Recon: FDA raps Merz over misleading Instagram posts for wrinkle treatment; J&J sues Biden Administration over 340B drug payments

• FDA scolds Merz over ‘misleading’ Instagram posts featuring interior designer Nate Berkus (STAT)
• Vertex’s upcoming sciatica trial readout is a high-stakes moment in its quest to quell pain (STAT)
• Johnson & Johnson sues Biden administration over payment terms for 340B hospitals (STAT)
• With GOP control of Congress, Trump has broad power to reshape health care (STAT)
• Merck buys into PD-1/VEGF space as Summit comes for Keytruda (Endpoints)
• Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster (STAT)

• Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved (STAT)
• BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots (Endpoints)
• New Zealand clears first clinical trial of epigenetic editing for hepatitis B (Endpoints)
• Merck KGaA’s life science unit is still feeling the Covid demand decline (Endpoints)
• EU Medtech Association Focuses On Innovation And Digital At 65th Anniversary (MedTech Insight)
• La French Touch: How France Has Built a Reputation for Excellence In Medtech (MedTech Insight)

• Novo Nordisk to phase out its production of human insulin pens globally (Endpoints)
• Mild Alzheimer’s patients won’t save Cassava Sciences (STAT)
• Neurogene and the race to the bottom of gene therapy (STAT)
• As bluebird projects more commercial demand, the biotech continues to seek cash (Endpoints)
• Zai Lab aims to raise $200M; Kronos Bio to seek ‘strategic’ options (Endpoints)
• Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact (Endpoints)
• GSK makes case for Blenrep's return with new blood cancer survival data (Endpoints)

• A telehealth friend in the new Congress, and Amazon’s smile on a mental health service (STAT)
• Haemonetics to close California facility, lay off 75 people (MedTech Dive)
• GE Healthcare’s head-only MRI scanner cleared by the FDA (MedTech Dive)
• Dean Kamen, insulin pump pioneer, wants to shake up diabetes tech (MedTech Dive)
• Livanova hits sleep apnea trial goals, plans FDA filing (MedTech Dive)

• FDA breakthrough device decisions rebound after recent declines (MedTech Dive)
• Facing a dialogue with RFK Jr., a top FDA official mounts a public defense of vaccines (STAT)
• Tech and social media bans alone cannot fix teen mental health (STAT)